Premium
Cooperative Treatment of Metastatic Breast Cancer Using Host–Guest Nanoplatform Coloaded with Docetaxel and siRNA
Author(s) -
Wang Dangge,
Wang Tingting,
Xu Zhiai,
Yu Haijun,
Feng Bing,
Zhang Junying,
Guo Chengyue,
Yin Qi,
Zhang Zhiwen,
Li Yaping
Publication year - 2016
Publication title -
small
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.785
H-Index - 236
eISSN - 1613-6829
pISSN - 1613-6810
DOI - 10.1002/smll.201502913
Subject(s) - small interfering rna , cancer research , docetaxel , rna interference , metastasis , cancer , photothermal therapy , chemistry , metastatic breast cancer , breast cancer , materials science , medicine , transfection , rna , nanotechnology , gene , biochemistry
Conventional chemotherapy shows moderate efficiency against metastatic cancer since it targets only part of the mechanisms regulating tumor growth and metastasis. Here, gold nanorod (GNR)‐based host‐guest nanoplatforms loaded with docetaxel (DTX) and small interfering RNA (siRNA)‐p65 (referred to as DTX‐loaded GNR (GDTX)/p65) for chemo‐, RNA interference (RNAi), and photothermal ablation (PTA) cooperative treatment of metastatic breast cancer are reported. To prepare the nanoplatform, GNRs are first coated with cyclodextrin (CD)‐grafted polyethylenimine (PEI) and then loaded with DTX and siRNA through host–guest interaction with CD and electrostatic interaction with PEI, respectively. Upon near‐infrared laser irradiation, GNRs generate a significant hyperthermia effect to trigger siRNA and DTX release. DTX reduces tumor growth by inhibiting mitosis of cancer cells. Meanwhile, siRNA‐p65 suppresses lung metastasis and proliferation of cancer cells by blocking the nuclear factor kappa B (NF‐κB) pathway and downregulating the downstream genes matrix metalloproteinase‐9 (MMP‐9) and B cell lymphoma‐2 (Bcl‐2). It is demonstrated that GDTX/p65 in combination with laser irradiation significantly inhibits the growth and lung metastasis of 4T1 breast tumors. The antitumor results suggest promising potential of the host–guest nanoplatform for combinational treatment of metastatic cancer by using RNAi, chemotherapy, and PTA.